Yuhan Corp - Company Profile
Powered by 
All the data and insights you need on Yuhan Corp in one report.
$295
- Save hours of research time and resources with
our up-to-date Yuhan Corp Strategy Report
- Understand Yuhan Corp position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Yuhan Corp Catalyst Calendar
Proactively evaluate Yuhan Corp’s catalyst impacts to stay ahead of the competition & improve corporate planning. Bolster business development with timely opportunities.
A sample of Yuhan Corp Catalyst Calendar data
| Event Date | Event Type | Company Name | Ticker Symbol | Drug Name | Therapy Area | Indication | Source Type |
|---|---|---|---|---|---|---|---|
| 01 Nov 2020 | GDCTWXYZ | Lorem | Lorem | Lorem | WXYZ | Planned | Lorem |
| 09 Mar 2020 | Phase II Trial Initiation | Boryung Pharmaceutical Co Ltd; Dong-A Socio Holdings Co Ltd; Seoul National University Hospital; Yuhan Corp | 000100; 000640; 003850 | gemcitabine hydrochloride; oxaliplatin; pegfilgrastim | Oncology | Peripheral T-Cell Lymphomas (PTCL) | Clinical Trial Registry |
| 01 Feb 2020 | Phase III Trial Initiation | Korea Drug Development Fund; Parexel International Corp; Yuhan Corp | 000100 | lazertinib | Oncology | Lung Adenocarcinoma; Non-Small Cell Lung Cancer | Clinical Trial Registry |
| 25 Oct 2019 | Phase II Trial Initiation | Yuhan Corp | 000100 | (amlodipine besylate + telmisartan); rosuvastatin calcium | Cardiovascular; Metabolic Disorders | Hyperlipidemia; Hypertension | GD Estimates |
Feature
Catalyst Calendar provides forecasted drug development milestones within the Pharma industry including expected timing, expected outcomes and possible financial impacts.
Benefit
Access:
- Trial Events for trials conducted globally by a company, university, institute or CRO: Trial Initiation, Trial Completion, Trial Results
- Regulatory Events related to drug filings with regulatory bodies, approvals and commercial launches. This is covered for the US, EU and Japan
- Intellectual Property Events for patent and exclusivity expiry specific to the US, EU and Japan: Constraining Patent Expiry (US/EU/Japan), Drug Expiry (US/EU/Japan), Commercial Launch (US/EU/Japan)
Value
Proactively evaluate companies and catalyst impacts
Stay ahead of the competition & improve corporate planning
Bolster business development with timely opportunities
Premium databases is part of our industry range of products
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer